X4 Pharmaceuticals develops and sells oral treatments for rare blood diseases, led by XOLREMDI (mavorixafor) for WHIM syndrome. It last closed at $3.00 on Nov 20, up 1.35% on the day. For the quarter ended Sep 2026, XFOR reported EPS of -$0.16 on revenue of $2.8M, with revenue up 75.0% from a year ago. Over its last 8 reports the stock moved an average of 17.0% the session after earnings. Over the last 12 months XFOR insiders bought $12K of stock on the open market and sold $463K, according to SEC Form 4 filings.
AI Auto Pilots
Is XFOR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XFOR.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on XFORStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
XFOR · as of the Nov 20 close · updated each morning
Downtrend
The stock is 6% below its 20 day and 3% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 46). The nearest support is the Pivot at $2.98, and the nearest resistance the Pivot R1 at $3.08.
Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 8.1%/day
Key levels
$4.8352 week high+61.0%
$3.76200 day average+25.3%
$3.55100 day average+18.3%
$3.46Swing high (Nov 9)+15.3%
$3.1820 day average+6.0%
$3.0950 day average+3.0%
$3.08Pivot R1+2.7%
$3.00Last close
$2.98Pivot−0.7%
$2.91Pivot S1−3.0%
$2.90Swing low (Nov 5)−3.3%
$2.4352 week low−19.0%
Indicators
RSI (14)
45.78
Middle of its range
Neutral
MACD
-0.04
Below its signal line
Bearish
Stochastic
30.2
Middle of its range
Neutral
ADX (14)
17.0
No clear trend
Williams %R
-66.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
-99.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−5.7%
Change over 10 sessions
Bearish
ATR (14)
$0.24
Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 17.8%/day
Key levels
$4.8352 week high+61.0%
$3.76200 day average+25.3%
$3.55100 day average+18.3%
$3.46Swing high (Nov 9)+15.3%
$3.1820 day average+6.0%
$3.0950 day average+3.0%
$3.08Pivot R1+2.7%
$3.00Last close
$2.98Pivot−0.7%
$2.91Pivot S1−3.0%
$2.90Swing low (Nov 5)−3.3%
$2.4352 week low−19.0%
Indicators
RSI (14)
41.56
Middle of its range
Neutral
MACD
-0.26
Below its signal line
Bearish
Stochastic
30.6
Middle of its range
Neutral
ADX (14)
16.1
No clear trend
Williams %R
-70.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
-75.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−14.3%
Change over 10 sessions
Bearish
ATR (14)
$0.53
Typical daily range, 17.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XFOR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how XFOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow XFOR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for XFORHow many large options trades hit XFOR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in XFOR in the last 90 days.
From SEC Form 4 filings by XFOR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XFOR is in one of them and how their past XFOR trades turned out.
X4 Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that develops and sells treatments for rare blood diseases. Its main product, XOLREMDI (mavorixafor), is an oral capsule approved in the United States for WHIM syndrome, a rare immune disorder, and patients can obtain it through a specialty pharmacy. The company is also developing mavorixafor for chronic neutropenia, a rare blood condition, and works with partners to commercialize its products outside the United States.